Home › Research › Biomarkers
Comparison of Plasma p-tau217 and [18F]FDG-PET for Identifying Alzheimer Disease in People With Early-Onset or Atypical Dementia
Quispialaya KM, Therriault J, Aliaga A, Benedet AL, Ashton NJ, Karikari T, Cassa Macedo A, Rahmouni N et al.. Neurology, 2024-12-23
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background and objectives To compare the diagnostic performance of an immunoassay for plasma concentrations of phosphorylated tau (p-tau) 217 with visual assessments of fluorine-18 fluorodeoxyglucose [ 18 F]FDG-PET in individuals who meet appropriate use criteria for Alzheimer dementia (AD) biomarker assessments. Methods We performed a retrospective analysis of individuals with early-onset (age 18 F]FDG-PET scans, amyloid-PET scans, and plasma p-tau217 quantifications. To determine whether the [ 18 F]FDG-PET images were compatible with AD, images were visually rated by 2 nuclear medicine experts. Using a contingency analysis, we evaluated the accuracy of [ 18 F]FDG-PET scan interpretation and plasma p-tau217 for an AD biomarker profile in CSF and for amyloid-PET positivity. Results A total of 81 individuals with early onset and/or atypical dementia were included in this study (mean age = 65 years; 48/81 female (59%). Both [ 18 F]FDG-PET and plasma p-tau217 showed high levels of agreement with reference standard AD biomarkers ([ 18 F]FDG-PET area under the curve [AUC]: 71%; plasma p-tau217 AUC: 81%). Although both biomarkers had similar specificity for AD [ 18 F]FDG-PET: 70%, CI: 0.56-0.81; plasma p-tau217: 70%, CI: 0.56-0.81), plasma p-tau217 had higher sensitivity for AD (plasma p-tau217: 97%, CI: 0.85-0.99 vs [ 18 F]FDG-PET: 73%, CI: 0.57-0.85) ( p = 0.01). Overall accuracy was also higher for plasma p-tau217 (AUC = 84%, CI: 0.75-0.93 vs 72%, CI: 0.60-0.83 of [ 18 F]FDG-PET) ( p = 0.02). The same pattern of results was observed when using amyloid-PET as the reference standard. Discussion Our study provides evidence that plasma p-tau217 has strong discriminative accuracy for AD among patients with early-onset and/or atypical dementia assessed in specialized settings. Future work should replicate these findings in secondary care settings.
What this study adds
Evidence grade: Low
The record lists 81 participants. In 81 people with early-onset or atypical dementia, a blood test for p-tau217 identified Alzheimer's disease biomarker profiles more accurately than visual reading of FDG-PET scans. The authors call for these findings to be replicated in other care settings before use in practice.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Quispialaya, K. M., Therriault, J., Aliaga, A., Benedet, A. L., Ashton, N. J., Karikari, T., et al. (2025). Comparison of Plasma p-tau217 and [18F]FDG-PET for Identifying Alzheimer Disease in People With Early-Onset or Atypical Dementia. Neurology. https://doi.org/10.1212/wnl.0000000000210211
Vancouver
Quispialaya KM, Therriault J, Aliaga A, Benedet AL, Ashton NJ, Karikari T, et al. Comparison of Plasma p-tau217 and [18F]FDG-PET for Identifying Alzheimer Disease in People With Early-Onset or Atypical Dementia. Neurology. 2025. doi:10.1212/wnl.0000000000210211. PMID: 39715476.
BibTeX
@article{quispialaya2025-39715476,
author = {Quispialaya, K. M. and Therriault, J. and Aliaga, A. and Benedet, A. L. and Ashton, N. J. and Karikari, T. and Cassa Macedo, A. and Rahmouni, N. and others},
title = {{Comparison of Plasma p-tau217 and [18F]FDG-PET for Identifying Alzheimer Disease in People With Early-Onset or Atypical Dementia}},
journal = {Neurology},
year = {2025},
doi = {10.1212/wnl.0000000000210211},
pmid = {39715476},
url = {https://doi.org/10.1212/wnl.0000000000210211}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results A total of 81 individuals with early onset and/or atypical dementia were included in this study (mean age = 65 years; 48/81 female (59%).
- Overall accuracy was also higher for plasma p-tau217 (AUC = 84%, CI: 0.75-0.93 vs 72%, CI: 0.60-0.83 of [ 18 F]FDG-PET) ( p = 0.02).
- The same pattern of results was observed when using amyloid-PET as the reference standard.
- Future work should replicate these findings in secondary care settings.
Why it matters
In 81 people with early-onset or atypical dementia, a blood test for p-tau217 identified Alzheimer's disease biomarker profiles more accurately than visual reading of FDG-PET scans. The authors call for these findings to be replicated in other care settings before use in practice.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants81
- Evidence strengthLow
How this study scored 54/100
Published in a leading specialty journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 1 / 4 | 81 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 16 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 5.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 4.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 2 / 4 | Cited 16 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Pedro Rosa‐Neto: h-index 89 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 18 institution(s) in 6 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39715476) |
| Free to read | 2 / 2 | Free to read |
| Total | 54 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 25.
Related studies in Biomarkers from nearby years
Also tagged “phosphorylated”
733 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 733 tagged studies.